Howard Kaufman

Howard Kaufman, M.D., is a leading authority on melanoma immunotherapy. He provides ongoing clinical guidance to the company. He is the past President of the Society for the Immunotherapy of Cancer (SITC), a leading scientific organization in the immune-oncology field and has conducted over fifty cancer vaccine and immunotherapy clinical trials.

Dr. Kaufman has maintained an NIH-funded laboratory in tumor immunology for over fifteen years. He received his M.D. degree from Loyola University, did a residency in General Surgery at Boston University and completed fellowship training in Tumor Immunology and Surgical Oncology at the National Cancer Institute. He has previously held appointments as Chief of the Division of Surgical Oncology and Associate Director of the Herbert Irving Comprehensive Cancer Center at Columbia University, in New York City. In 2009, he was recruited to be the first Director of the Rush University Cancer Center in Chicago and in 2014, he was recruited to New Jersey as the Chief Surgical Officer and Associate Director for Clinical Sciences at the Rutgers Cancer Institute of New Jersey.

Dr. Kaufman has published over 400 peer-reviewed scientific papers, books, review articles and abstracts and serves on the editorial board of several biomedical journals. He is the Editor-In-Chief of the Journal of Immunotherapy Applications and is a Senior Associate Editor at the Journal of Translational Medicine. He is a member of numerous professional societies and was elected President of the Society for Immunotherapy of Cancer. Dr Kaufman currently serves as Head, Research & Development at Immuneering Corporation based in Cambridge, Massachusetts.